دورية أكاديمية

Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women

التفاصيل البيبلوغرافية
العنوان: Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women
المؤلفون: Sandra Nunes, Catarina Moreira-Barbosa, Sofia Salta, Susana Palma de Sousa, Inês Pousa, Júlio Oliveira, Marta Soares, Licínio Rego, Teresa Dias, Jéssica Rodrigues, Luís Antunes, Rui Henrique, Carmen Jerónimo
المصدر: Cancers; Volume 10; Issue 10; Pages: 357
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2018
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: breast cancer, colorectal cancer, lung cancer, DNA methylation, epigenetic biomarker, cell-free DNA, liquid biopsy, detection
الوصف: Background: Breast (BrC), colorectal (CRC) and lung (LC) cancers are the three most common and deadly cancers in women. Cancer screening entails an increase in early stage disease detection but is hampered by high false-positive rates and overdiagnosis/overtreatment. Aberrant DNA methylation occurs early in cancer and may be detected in circulating cell-free DNA (ccfDNA), constituting a valuable biomarker and enabling non-invasive testing for cancer detection. We aimed to develop a ccfDNA methylation-based test for simultaneous detection of BrC, CRC and LC. Methods: CcfDNA from BrC, CRC and LC patients and asymptomatic controls were extracted from plasma, sodium-bisulfite modified and whole-genome amplified. APC, FOXA1, MGMT, RARβ2, RASSF1A, SCGB3A1, SEPT9, SHOX2 and SOX17 promoter methylation levels were determined by multiplex quantitative methylation-specific PCR. Associations between methylation and standard clinicopathological parameters were assessed. Biomarkers’ diagnostic performance was also evaluated. Results: A “PanCancer” panel (APC, FOXA1, RASSF1A) detected the three major cancers with 72% sensitivity and 74% specificity, whereas a “CancerType” panel (SCGB3A1, SEPT9 and SOX17) indicated the most likely cancer topography, with over 80% specificity, although with limited sensitivity. Conclusions: CcfDNA’s methylation assessment allows for simultaneous screening of BrC, CRC and LC, complementing current modalities, perfecting cancer suspects’ triage, increasing compliance and cost-effectiveness.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
العلاقة: https://dx.doi.org/10.3390/cancers10100357Test
DOI: 10.3390/cancers10100357
الإتاحة: https://doi.org/10.3390/cancers10100357Test
حقوق: https://creativecommons.org/licenses/by/4.0Test/
رقم الانضمام: edsbas.DA045D1C
قاعدة البيانات: BASE